Rebastinib tosylate

Overview

Rebastinib tosylate (DCC-2036 tosylate) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC 50 values of 0.8 nM and 4 nM against Abl1 WT and Abl1 T315I , respectively. Rebastinib tosylate potently inhibits CYP2C8 ( IC 50 = 0.0533 μM) and CYP2C9 ( IC 50 = 2.54 μM). Rebastinib tosylate allosterically inhibits Tie2 with an IC 50 of 0.63 nM. Rebastinib tosylate inhibits the transcriptional activity of FoxO1 . Rebastinib tosylate inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib tosylate induces Apoptosis . Rebastinib tosylate exerts anti-tumor activity in breast cancer . Rebastinib tosylate exerts anti-angiogenic effects. Rebastinib tosylate increases myotube diameter and improves reduced contractility. Rebastinib tosylate can be used in research related to triple-negative breast cancer , luminal breast cancer , pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Muscle Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Muscular Dystrophy | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > Tie | Products > Signaling Pathways > FOXO | Products > Signaling Pathways > Src

Product Information

• Catalog No.: HY-13024A
• CAS No.: 1033893-29-6
• Molecular Formula: C37H36FN7O6S
• Molecular Weight: 725.79
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source